Aytu BioScience Inc (AYTU) financials · rev $57.6M
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
Aytu BioScience Inc (AYTU) rev $57.6M.
| Line | FY2026 | FY2025 |
|---|---|---|
| Revenue | $57.6M | $66.4M |
| Cost of Revenue | $20.8M | $20.6M |
| Gross Profit | $36.8M | $45.8M |
| Operating Income | -$8.31M | -$7.83M |
| Net Income | -$14.3M | -$13.6M |
| EPS (Diluted) | -$1.16 | -$2.16 |
| Line | FY2026 | FY2025 |
|---|---|---|
| Total Assets | $105.0M | $124.2M |
| Current Assets | $61.8M | $79.2M |
| Cash & Equivalents | $26.3M | $31.0M |
| Inventory | $6.86M | $11.4M |
| PP&E | $385.0K | $532.0K |
| Total Liabilities | N/A | $105.2M† |
| Current Liabilities | $54.7M | $63.1M |
| Short-term Debt | $1.86M | $1.86M |
| Long-term Debt | $9.10M | $10.9M |
| Total Debt | $11.0M† | $10.9M |
| Shareholders' Equity | $35.3M | $19.0M |
| Retained Earnings | -$347.8M | -$333.5M |
† Total Liabilities: Derived: total assets minus shareholders’ equity (stored total liabilities equalled total assets, i.e. the liabilities-and-equity total).
† Total Debt: Derived: short-term debt plus long-term debt (no total debt stored).
| Line | FY2026 | FY2025 |
|---|---|---|
| Operating Cash Flow | $3.28M | -$1.94M |
| CapEx | $29.0K | $228.0K |
| Investing Cash Flow | -$29.0K | -$2.56M |
| Financing Cash Flow | -$7.90M | $15.4M |
| Net Change in Cash | -$4.64M | $10.9M |
| Free Cash Flow | $3.25M | -$2.17M |
FAQ
What is AYTU P/E and revenue?
Aytu BioScience Inc (AYTU) rev $57.6M.
What is AYTU revenue?
Aytu BioScience Inc last cached revenue is $57.6M (FY2026).
Is AYTU profitable?
Aytu BioScience Inc last cached net income is -$14.3M (FY2026).
What are AYTU total assets?
Aytu BioScience Inc last cached total assets are $105.0M (FY2026).
What is AYTU free cash flow?
Aytu BioScience Inc last cached free cash flow is $3.25M (FY2026).
Not investment advice. Cached statements, not a live tape.